A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Study Identifier
Immunogen 0007
CT.gov Identifier
NCT01237678
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Lung Cancer - Small Cell Lung Cancer (SCLC)
    • Study Drug
  • IMGN901
  • Carboplatin and Etoposide
    • Phase
    Phase 1/Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients must be 18 years old * Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease * ECOG performance status of 0, 1, or 2 * No prior systemic chemotherapy for the treatment of SCLC
    Exclusion Criteria:
    \- Pregnant or lactating females

    Protocol Summary

    The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.

    Study Locations

    Location
    Status
    Location
    Arizona Cancer Center @ UMC North
    Tucson, Arizona, United States, 85719
    Status
    Not applicable
    Location
    UCLA Oncology Center
    Los Angeles, California, United States, 90095
    Status
    Not applicable
    Location
    St. Joseph's Hospital
    Orange, California, United States, 92868
    Status
    Not applicable
    Location
    UCLA Hematology
    Pasadena, California, United States, 91105
    Status
    Not applicable
    Location
    UCLA Oncology Clinic
    Santa Monica, California, United States, 90404
    Status
    Not applicable
    Location
    UCLA Santa Clarita Valley Cancer Center
    Valencia, California, United States, 91355
    Status
    Not applicable
    Showing {first} - {last} of {total} Results